Dr. Reddy's Subsidiary Aurigene Oncology, Announced Phase 1 Results For Ribrecabtagene Autoleucel From SWASTH Study; All 8 Patients Achieved Clinical Response
Dr. Reddy's Subsidiary Aurigene Oncology, Announced Phase 1 Results For Ribrecabtagene Autoleucel From SWASTH Study; All 8 Patients Achieved Clinical Response
Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients.
印度雷待肯肿瘤治疗有限公司，印度雷克利有限公司的全资子公司，是一家临床阶段的生物技术公司，致力于为癌症治疗引入新颖有效的治疗方法，宣布来自SWASTH研究的Ribrecabtagene autoleucel (DRL-1801)的第1期结果——印度首个针对自体BCMA导向CAR-t细胞疗法的试验，治疗复发/难治性多发性骨髓瘤患者。该研究报告了头8名患者的初始结果。所有患者都接受过多次治疗，平均为5.5种先前疗法。大多数患者过去也接受过移植，并在移植后疾病进展。所有8名患者（100%）均获得临床反应，其中5/8（62.5%）达到严格的完全缓解。在安全性方面，没有任何患者出现细胞因子释放综合征（CRS）或神经毒性的高级事件。
